News

Verastem Shares Rise 25% as FDA Issues Breakthrough Therapy Designation for Ovarian Cancer Drug

May 25, 2021 (Investorideas.com Newswire) Verastem Inc. shares reached a new 52-week high after the company reported its VS-6766 in combination with defactinib was granted breakthrough therapy designation by the FDA for treatment of recurrent low-grade serous ovarian cancer.

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

Leave a reply

Your email address will not be published. Required fields are marked *

More in:News

Next Article:

0 %